Table 3.
Subgroup analyses: hazard ratios for overall survival (SHI) following treatment in DKG-certified ovarian cancer centers
| Variable | Category | Univariable Cox-regression | Multivariable Cox-regressiona | ||||||
|---|---|---|---|---|---|---|---|---|---|
| p | HR | lower CI | upper CI | P | HR | lower CI | upper CI | ||
| Age | 18–59 | 0.719 | 1.022 | 0.906 | 1.154 | 0.080 | 0.890 | 0.782 | 1.014 |
| 60–79 | < 0.001 | 0.836 | 0.782 | 0.893 | 0.008 | 0.902 | 0.836 | 0.973 | |
| 80+ | < 0.001 | 0.770 | 0.693 | 0.855 | 0.001 | 0.838 | 0.753 | 0.933 | |
| Year of diagnosis | 2009-11 | < 0.001 | 0.810 | 0.733 | 0.895 | 0.055 | 0.892 | 0.793 | 1.002 |
| 2012-14 | < 0.001 | 0.810 | 0.736 | 0.892 | 0.344 | 0.950 | 0.854 | 1.056 | |
| 2015-17 | < 0.001 | 0.638 | 0.570 | 0.715 | < 0.001 | 0.803 | 0.717 | 0.900 | |
| Tumor characteristics: stage | Local (without C77-C79) | < 0.001 | 0.657 | 0.572 | 0.754 | 0.020 | 0.834 | 0.716 | 0.972 |
| Regional metastasis (C77, without C78-C79) | 0.265 | 0.854 | 0.647 | 1.127 | 0.745 | 1.060 | 0.745 | 1.508 | |
| Distant metastasis (C78-C79) | < 0.001 | 0.736 | 0.687 | 0.788 | 0.001 | 0.878 | 0.814 | 0.946 | |
| Hospital beds | 1–299 | 0.007 | 0.500 | 0.302 | 0.828 | 0.041 | 0.642 | 0.420 | 0.983 |
| 300–499 | 0.027 | 0.865 | 0.760 | 0.983 | 0.087 | 0.896 | 0.790 | 1.016 | |
| 500–999 | 0.003 | 0.846 | 0.758 | 0.943 | 0.004 | 0.842 | 0.748 | 0.947 | |
| 1000+ | 0.001 | 0.830 | 0.742 | 0.930 | 0.426 | 0.956 | 0.856 | 1.068 | |
aadjusted for age, year of diagnosis, elixhauser comorbidities and hospital characteristics if not stratified by the same variable